TY - JOUR A1 - Tan, Chee-Kiat T1 - Entecavir : A review Y1 - 2006/1/1 JF - Hepatitis B Annual JO - Hep B Annual SP - 35 EP - 53 VL - 3 IS - 1 UR - https://www.hepatitisbannual.org/article.asp?issn=0972-9747;year=2006;volume=3;issue=1;spage=35;epage=53;aulast=Tan N2 - Entecavir is the newest and most potent nucleoside analog to be licensed worldwide for the treatment of chronic hepatitis B infection. It has been shown to be more effective than lamivudine and adefovir in direct head-to-head comparison trials. It is also useful in the treatment of lamivudine-refractory patients. Entecavir is safe with no significant difference in adverse effects compared to lamivudine and adefovir. Available data for up to 2 years of continuous therapy showed no development of viral resistance in nucleos(t)ide-naοve patients. Resistance to entecavir occurs only in patients previously exposed to lamivudine and occurs at a rate of 9% after 2 years of continuous therapy with entecavir. ER -